Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Intervacc ABFRA:2E9 -2.57%63 PS Ratio is 18.98 as of Jul. 16, 2026, which is 33% below its 10-year median of 28.15. GuruFocus rates FRA:2E9 with a GF Score™ of 63/100 and a GF Value™ of €0.08. The stock has 5 warning signs investors should review. Among 930 Biotechnology companies, Intervacc AB ranks worse than 67.1% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Intervacc AB's share price is €0.0949.
Intervacc AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €0.01. Hence, Intervacc AB's PS Ratio for today is 18.98.
Warning Sign:
Intervacc AB stock PS Ratio (=23.36) is close to 1-year high of 24.11.
The historical rank and industry rank for Intervacc AB's PS Ratio or its related term are showing as below:
FRA:2E9'
s PS Ratio Range Over the Past 10 Years
Min: 0.9 Med: 28.15 Max: 897.17
Current: 23.15
During the past 12 years, Intervacc AB's highest PS Ratio was 897.17. The lowest was 0.90. And the median was 28.15.
FRA:2E9's PS Ratio is ranked worse than 67.1% of 930
companies
in the Biotechnology industry
Industry Median: 9.655
vs FRA:2E9: 23.15
Intervacc AB revenue per share has been in decline over the past 3 years.
During the past 12 months, the average Revenue per Share Growth Rate of Intervacc AB was -58.20% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -21.90% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 1.90% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -34.20% per year.
During the past 12 years, Intervacc AB's highest 3-Year average Revenue per Share Growth Rate was 20.30% per year. The lowest was -67.50% per year. And the median was -21.90% per year.
Back to Basics: PS Ratio
Intervacc AB (FRA:2E9) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Intervacc AB PS Ratio Related Terms
Intervacc AB PS Ratio Historical Data
* Premium members only.
The historical data trend for Intervacc AB's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Intervacc AB's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Intervacc AB PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Intervacc AB's PS Ratio distribution charts can be found below:
* The bar in red indicates where Intervacc AB's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Intervacc AB's PS Ratio for today is calculated as
Intervacc AB's Share Price of today is €0.0949. Intervacc AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.01.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Intervacc AB (FRA:2E9) has a PS Ratio of 18.98 as of Jul. 16, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Intervacc AB and its competitors. This is 33% below median its historical median of 28.15. Over the past decade, Intervacc AB's PS Ratio has ranged from 0.90 to 897.17. According to the industry distribution chart, Intervacc AB ranks #624 out of 930 companies in the Biotechnology industry, placing it in the top 67.1%.
Is Intervacc AB's PS Ratio too high?
Intervacc AB's current PS Ratio of 18.98 is 33% below median its 10-year median of 28.15. Over the past 10 years, this metric has ranged from a low of 0.90 to a high of 897.17. The Biotechnology industry median PS Ratio is 9.66. Intervacc AB's value of 18.98 is 96.6% above this industry median. Based on the distribution chart, Intervacc AB ranks #624 out of 930 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Intervacc AB has a GF Score™ of 63/100, reflecting its overall financial health beyond just this single metric.
How does Intervacc AB's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Intervacc AB ranks #624 out of 930 companies for PS Ratio. This places Intervacc AB in the lower half of its industry. The industry median PS Ratio is 9.66. Intervacc AB's value of 18.98 is 96.6% above this benchmark. Historically, Intervacc AB's own PS Ratio has ranged from 0.90 to 897.17 over the past decade. While the company's 10-year median is 28.15 vs. the industry median of 9.66, Intervacc AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.66, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Intervacc AB's current PS Ratio of 18.98 is 96.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Intervacc AB and its competitors. For the Biotechnology industry, the median PS Ratio is 9.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Intervacc AB's current PS Ratio is 18.98, which is 33% below median its own 10-year median of 28.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intervacc AB stock overvalued right now?
Intervacc AB (FRA:2E9) has a current PS Ratio of 18.98. The stock's GF Value™ is €0.08, compared to a current price of €0.09 — trading 18.6% above its estimated fair value. The current PS Ratio is 18.98, which is 33% below median its 10-year median of 28.15 and 96.6% above the Biotechnology industry median of 9.66. Intervacc AB's overall GF Score™ is 63/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Intervacc AB (FRA:2E9), the current PS Ratio is 18.98 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Intervacc AB (FRA:2E9) Overvalued in 2026?
Based on GuruFocus' analysis, Intervacc AB stock appears to be overvalued.
The current stock price of €0.09 is trading 18.6% above its estimated GF Value™ of €0.08.
Key valuation signals for FRA:2E9:
PS Ratio: 18.98 (33% below median its 10-year median of 28.15)
GF Value™: €0.08 vs. price of €0.09 (18.6% above fair value)
Industry Position: 96.6% above the Biotechnology median (#624 of 930)
No single metric tells the full story. See the FRA:2E9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Intervacc AB is a biotechnology company. It develops new vaccines based on recombinant proteins to meet the increasing need for effective vaccines in animal health care. The company through its subsidiary focuses on diagnostics in the Swedish animal health market and offers bacteriological and mycological analyses on the Swedish market.
63GF Score
Get the complete analysis for FRA:2E9
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2E9 has been successfully added to your 
